Time to Shift from the Conventional Treatment



NEUROPATHY SYMPTOMS:

Improvement in sensation - 93% Reduction of burning sensation 94% Reduction in Numbness 93% Reduction in Spontaneous Pain 89% mprovement in Thermal Sensitivity 91%

I THE TOTAL TOTAL

Inhibit The Conversion of Glucose to Sorbitol - Improves NCV

Epalrestat the effective ARI



Suppression of Polyol Pathway - the effective treatment

Suppression of polyol pathway may be an important key to efficient treatment for diabetic peripheral neuropathy

Diabetes Care 29:1538-1544, 2006

Epalrestat & Methylcobalamin FDA approved treatment in Diabetic Neuropathy

Epalrestat and Methylcobalamin are the only medicine approved by the FDA for the treatment of Diabetic Neuropathy.

International Journal of Universal Pharmacy and Bio Sciences 2(2): March-April 2013

Clinical trials proved the efficacy of Mepal in Diabetic Gastroparesis



DIABETIC GASTROPARESIS

Patients with gastroparesis are often asymptomatic, but diabetic gastroparesis may influence the absorption of oral antidiabetics and glycemic control. In the present study, epalrestat, an aldose reductase inhibitor, significantly increased the number of 3 cpm waves on EGG and improved the spectral analytical parameters of heart rate variability, suggesting that epalrestat may be useful for the treatment of diabetic gastroparesis.

Internal Medicine Vol. 42, No. 8 (August 2003) p 655-664


Faster & Better resolution

In Painful Diabetic Neuropathy and Diabetic Gastroparesis

THE PALES

MEPAL Improves electrical activity of stomach
MEPAL Improves decreased gastric motility in diabetic patients






Dose 1 Tab/day for 12 weeks

Time to Shift from the Conventional Treatment

Diabetic Patients Suffering from







Inhibit The Conversion of Glucose to Sorbitol - Improves NCV

Epalrestat the effective ARI



Suppression of Polyol Pathway - the effective treatment

Suppression of polyol pathway may be an important key to efficient treatment for diabetic peripheral neuropathy

Diabetes Care 29:1538-1544, 2006

Epalrestat & Methylcobalamin FDA approved treatment in Diabetic Neuropathy

Epalrestat and Methylcobalamin are the only medicine approved by the FDA for the treatment of Diabetic Neuropathy.

International Journal of Universal Pharmacy and Bio Sciences 2(2): March-April 2013

Mepal alleviate low back pain and sciatica

That MeCbl may have potential analgesic effects in experimental and clinical studies. For example: MeCbl alleviated pain behaviors in diabetic neuropathy, low back pain and neuralgia. MeCbl improved nerve conduction, promoted the regeneration of injured nerves, and inhibited ectopic spontaneous discharges of injured primary sensory neuron.

- Neural Plasticity Volume November 2013

No Giddiness No **Drowsiness**



Faster & Better resolution

In Painful Diabetic Neuropathy



Treats the symptoms and cause

NEUROPATHY SYMPTOMS:

Improvement in sensation - 93% Reduction of burning sensation 94% Reduction in Numbness 93% Reduction in Spontaneous Pain 89% Improvement in Thermal Sensitivity 91%

1 Tab/day for 12 weeks